12 min listen
Takayuki Yoshino on the DESTINY-CRC01 trial
Takayuki Yoshino on the DESTINY-CRC01 trial
ratings:
Length:
6 minutes
Released:
Jun 1, 2021
Format:
Podcast episode
Description
Takayuki Yoshino (National Cancer Center Hospital East, Kashiwa, Japan) discusses the DESTINY-CRC01 trial on trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer.Read the full article:https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00086-3/fulltextContinue this conversation on social!Follow us today at...https://twitter.com/thelancet & https://Twitter.com/TheLancetOncolhttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv
Released:
Jun 1, 2021
Format:
Podcast episode
Titles in the series (100)
The Lancet Oncology: August 11, 2008 by The Lancet Oncology in conversation with